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IL-37 protects against obesity-induced
inﬂammation and insulin resistance
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Cytokines of the IL-1 family are important modulators of obesity-induced inﬂammation and
the development of systemic insulin resistance. Here we show that IL-1 family member IL-37,
recently characterized as an anti-inﬂammatory cytokine, ameliorates obesity-induced
inﬂammation and insulin resistance. Mice transgenic for human IL-37 (IL-37tg) exhibit
reduced numbers of adipose tissue macrophages, increased circulating levels of adiponectin
and preserved glucose tolerance and insulin sensitivity after 16 weeks of HFD. In vitro
treatment of adipocytes with recombinant IL-37 reduces adipogenesis and activates AMPK
signalling. In humans, elevated steady-state IL-37 adipose tissue mRNA levels are positively
correlated with insulin sensitivity and a lower inﬂammatory status of the adipose tissue.
These ﬁndings reveal IL-37 as an important anti-inﬂammatory modulator during obesity-
induced inﬂammation and insulin resistance in both mice and humans, and suggest that
IL-37 is a potential target for the treatment of obesity-induced insulin resistance and type
2 diabetes.
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O
besity has reached epidemic proportions worldwide1 and
predisposes to the development of metabolic diseases,
including type 2 diabetes and cardiovascular diseases.
In obesity, adipocytes produce pro-inﬂammatory cytokines
and chemokines2 that can attract and activate macrophages3,4
and other immune cells5, resulting in chronic low-grade
inﬂammation5–7. The enhanced inﬂammatory status, illustrated
by the production of pro-inﬂammatory cytokines, directly
interferes with the insulin signalling pathway8,9, eventually
leading to systemic insulin resistance and the subsequent
development of type 2 diabetes10,11.
Multiple pro-inﬂammatory cytokines have been identiﬁed that
play a detrimental role in obesity-induced inﬂammation and
insulin resistance, such as interleukin (IL)-1b and tumour
necrosis factor-a (TNFa). However, cytokines that are able to
restore the immunological misbalance in obesity have been less
well studied. The IL-1 family consists of 11 members12, of which
IL-1a, IL-1b, IL-1 receptor antagonist and IL-18 have been shown
to play a pivotal role during obesity by modulating inﬂammatory
responses13–19. Only recently has IL-1 family member IL-37,
isolated in silico in the year 2000 (ref. 20), been identiﬁed for its
anti-inﬂammatory actions by inhibiting innate responses21.
During acute and chronic inﬂammation, IL-37 shifts the
cytokine balance away from excessive inﬂammation22, thereby
showing potency as a key factor to restore the inﬂammatory
balance in obesity. The IL-37 gene has been mapped to
chromosome 2 (ref. 23) and exists in ﬁve splice variants
(IL-37a–e)20,24–27. IL-37b is the most complete variant
containing ﬁve of the six exons and lacking a signal peptide.
The IL-37 precursor contains a classic caspase-1 cleavage site, and
caspase-1 processing appears to be required for nuclear
translocation of IL-37 and its intracellular anti-inﬂammatory
properties28,29. An instability element in exon 5 is known to
control IL-37 messenger RNA expression. Subsequently, in the
absence of inﬂammation, mRNA levels of IL-37 are rapidly
degraded. In contrast, an inﬂammatory stimulus stabilizes IL-37
mRNA levels, thereby permitting its anti-inﬂammatory actions30.
Previous studies have shown that IL-37 transgenic mice are
protected from colitis31 and lipopolysaccharide (LPS)-induced
shock21.
In the present study, we investigated whether IL-37 can
counteract obesity-induced adipose tissue inﬂammation and
protect against the development of insulin resistance. This was
tested by examining adipose tissue samples from 80 humans for
the expression of IL-37 and its relationship to inﬂammatory and
metabolic markers. We also studied the effects of high-fat diet
(HFD) in a unique human IL-37 transgenic mouse model and the
in vitro properties of IL-37 on adipocyte function, insulin and
AMPK signalling. We provide evidence for a role of IL-37 in
ameliorating inﬂammation and insulin sensitivity in obesity.
Results
IL-37 is expressed in human adipose tissue. First we evaluated
the gene expression of IL-1 family members, including IL-37, in
human adipose tissue in mature adipocytes (MAs) and stromal
vascular cells (SVF) isolated from seven subjects. Whereas IL-1b,
IL-1Ra and IL-18 showed higher expression in SVF, IL-37 was the
only cytokine with higher mRNA levels in MA compared with
SVF (Fig. 1a). mRNA analysis of paired adipose tissue samples of
individuals demonstrated clear expression of IL-37 in adipose
tissue, which was similar in visceral adipose compared with
subcutaneous adipose tissue (Fig. 1b). In addition, western blot
analysis revealed the presence of IL-37 in human adipose tissue at
B37 kDa (Fig. 1c). However, in adipose tissue IL-37 migrates at
B37 kDA, likely to be due to homodimerization, which was also
reported elsewhere21. Moreover, the presence of IL-37 in human
adipose tissue was conﬁrmed by measuring the protein by a
speciﬁc enzyme-linked immunosorbent assay (Supplementary
Fig. 1).
IL-37 reduces diet-induced obesity in mice. To date, no com-
plete mouse homologue for IL-37 has been found. Therefore, to
examine the properties of IL-37 in a model of obesity in vivo,
we employed a transgenic mouse strain expressing human IL-37
(IL-37tg) in all cells using a cytomegalovirus promoter21. The
animals were fed High fat diet (HFD) (45% kcal derived from fat)
or a control low-fat diet (LFD) (10% kcal derived from fat) for 16
weeks, and body weight gain and food intake were compared with
wild-type (WT) animals (Fig. 2a). Starting body weight was
similar between the WT and IL-37tg animals, yet body weight
gain was signiﬁcantly lower in HFD-fed IL-37tg mice compared
with WT animals ( 41% on HFD and  46% on LFD) (Fig. 2b),
even though total caloric intake was similar in both genotypes
(Fig. 2c). In line with lower body weight and epididymal white
adipose tissue (WAT) mass (Fig. 2d), adipocyte size was smaller
in the IL-37tg mice compared with WT animals (Fig. 2e), and
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Figure 1 | IL-37 is expressed in human adipose tissue. Human adipose
tissue was used to determine IL-37 expression. (a) mRNA levels of IL-1b,
IL-1Ra, IL-18 and IL-37 in MA and SVF of subcutaneous and visceral adipose
tissue, n¼ 7. (b) mRNA levels of IL-37 in subcutaneous and visceral adipose
tissue, n¼ 17. (c) IL-37 was detected with western blotting analysis in
human subcutaneous tissue, n¼ 8. Error bars are shown as mean±s.e.m.
*Po0.05, **Po0.01, ***Po0.001 (one-way analysis of variance). SVF,
stromal vascular fraction; MA, mature adipocytes.
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paralleled by lower leptin (Fig. 2f) and strikingly higher plasma
adiponectin levels (Fig. 2g).
IL-37 lowers liver and plasma lipids. After HFD feeding, liver
weight was lower in the presence of human IL-37 (Fig. 2h), which
was paralleled by lower liver hepatic triglyceride content in
HFD-fed IL-37tg mice as compared with WT animals (Fig. 2j)
and by reduced levels of hepatic steatosis on HFD feeding, as
visualized by haematoxylin and eosin staining (Fig. 2i). However,
no signiﬁcant differences were found in MCP-1 and F4/80 gene
expression levels in the liver (Fig. 2k,l). Plasma cholesterol was
signiﬁcantly lower after HFD feeding in IL-37 animals compared
with HFD-fed WT (Fig. 2m). Free fatty acid (FA) and triglyceride
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Figure 2 | IL-37 reduces diet-induced obesity in mice. IL-37tg and WTmice were fed an LFD or HFD for 16 weeks. (a) Body weight development
and (b) body weight gain on LFD or HFD feeding. (c) Total caloric intake during 16 weeks of LFD or HFD. (d) Epididymal WAT (eWAT) weight
after 16 weeks of LFD or HFD and (e) adipocyte size. Plasma concentrations of (f) leptin and (g) adiponectin after diet intervention. (h) Liver weights,
(i) haematoxylin and eosin (H&E) staining of liver sections; magniﬁcation  20 and (j) hepatic triglyceride (TG) content. qPCR analysis of macrophage
inﬁltration markers F4/80 (k) and MCP-1 (i) in liver. (m) Plasma cholesterol, (n) free FAs and (o) triglycerides after 16 weeks of LFD or HFD.
(p) H&E staining of brown adipose tissue; magniﬁcation  20. n¼ 10 mice per group. Error bars are shown as mean±s.e.m. *Po0.05, **Po0.01,
***Po0.001 (t-test or one-way analysis of variance). TG, triglycerides; FFA, free fatty acids.
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plasma levels in the animals showed similar tendencies towards
lower values in IL-37tg animals compared with WT mice after the
HFD intervention (Fig. 2n,o).
To learn more about potential mechanisms that may explain
lower body weight and amelioration in plasma lipid proﬁle, we
examined the brown adipose tissue, known to oxidize FAs for
heat production. Owing to the large energy consumption, brown
adipose tissue (BAT) highly contributes to plasma triglyceride
clearance32. Although UCP-1 and PGC-1a levels were not altered
in the IL-37tg mice compared with WT (Supplementary
Fig. 2a,b), we observed a marked reduction in BAT lipid
accumulation, in IL-37tg mice fed HFD compared with WT
animals (Fig. 2p).
IL-37 ameliorates diet-induced insulin resistance. After HFD
feeding, lower plasma insulin levels were observed in IL-37tg mice
compared with WT mice, suggestive of preserved insulin sensi-
tivity (Fig. 3a). Therefore, we performed an insulin tolerance test
(ITT) and oral glucose tolerance test (oGTT). The ITT revealed
that IL-37tg animals were partially protected against obesity-
induced insulin resistance (Fig. 3b). In addition, the oGTT test
demonstrated that IL-37tg animals had improved glucose toler-
ance on HFD feeding as compared with WT mice (Fig. 3c).
Acute effects of IL-37 on glucose tolerance. To determine
whether the beneﬁcial effects of IL-37 on insulin sensitivity were
independent of differences in body weight, we fed WT and
IL-37tg animals a short-term HFD containing 60% kcal derived
from fat for 4 days. The 4-day diet intervention did not affect
body weight (Supplementary Fig. S3). An oral GTT test revealed
that the HFD-fed WT animals developed glucose intolerance as
compared with the LFD-fed mice. In contrast, in the HFD-fed IL-
37tg animals, glucose tolerance was preserved as compared with
the mice receiving the LFD (Fig. 3d), suggesting that IL-37 directly
ameliorates the adverse effects on glucose tolerance induced by
chronic HFD feeding, and that this effect is independent of changes
in body weight.
We further assessed whether the improved glucose tolerance in
the IL-37tg mice was due to differences in the insulin-producing
b-cells. Islets were therefore stained for insulin and then mean
staining intensity was measured as marker for insulin content. In
IL-37tg mice, mean insulin staining intensity was lower compared
with WT mice in both LFD- and HFD-fed mice (Supplementary
Fig. 4a). In addition, islet hypertrophy was also observed in WT
mice (P¼ 0.06 (one-way analysis of variance)). However, in
IL-37tg mice, islet hypertrophy was not present (Supplementary
Fig. 4b,c). Moreover, no differences were seen in the number of
macrophages in the islets (Supplementary Fig. 4d). Together,
these observations suggest preserved b-cell function and thereby
improved metabolic control in IL-37tg mice after HFD.
IL-37 directly improves insulin sensitivity. We subsequently
investigated the effect of IL-37 on insulin sensitivity using an
in vitro approach. We revealed that silencing IL-37 hampers
insulin signalling in human HepG2 cells that were stimulated
with TNF-a or tunicamycin as inducers of insulin resistance8,33.
Stimulation of these cells with either TNF-a or tunicamycin
resulted in a signiﬁcant increase of steady-state levels of IL-37
mRNA after 4 and 8 h (Fig. 3e). As shown in Fig. 3f,
small interference RNA (siRNA)-mediated targeting to silence
endogenous IL-37 (see Supplementary Fig. S5) signiﬁcantly
reduced activation of insulin receptor substrate 1 (IRS-1) as
measured by tyrosine (Tyr) 941 phosphorylation. As a
consequence, phosphorylation of the downstream effector
molecule AKT was also reduced as compared with scrambled
siRNA-treated cells. As shown in Fig. 3g, these differences could
be partly explained by the increased activation of the
inﬂammatory kinases ERK1/2, JNK and IKK a/b in cells
silenced for IL-37. These kinases are known to cause insulin
resistance via inhibition of the insulin signalling pathway, for
example, by inhibition of IRS-1 (ref. 34). IL-37 downregulates the
phosphorylation of these kinases as reported before21.
IL-37 ameliorates diet-induced adipose tissue inﬂammation.
Furthermore, we investigated whether the IL-37tg mice were
protected against HFD-induced adipose tissue inﬂammation,
which may explain the improvement in insulin sensitivity.
Therefore, we ﬁrst investigated the adipose tissue of IL-37tg and
WT mice for the presence of different immune cells using
ﬂuorescence-activated cell sorting (FACS) analysis of the stromal
vascular fraction after 16 weeks of HFD feeding. Macrophage
numbers were lower in IL-37tg mice (F4/80þCD11bþ ,  20%,
Po0.05 (t-test); Fig. 4a). Similar reductions of other pro-
inﬂammatory cells were observed for NK cells (NK1.1þ ,  46%,
Po0.05 (t-test); Fig. 4b) and cytotoxic T cells (CD3þCD8þ ,
 32%, Po0.05 (t-test); Fig. 4c), whereas there was no change in
the amount of regulatory T cells (CD3þCD4þ , nonsigniﬁcant
(t-test); Fig. 4d) in the IL-37tg animals compared with WT
animals fed the HFD. The reduction in pro-inﬂammatory status
of the adipose tissue in the presence of IL-37 was conﬁrmed
by quantitative PCR (qPCR) analysis for various macrophage
markers. F4/80, CD11c and MCP-1 gene expression levels were all
substantially lower in HFD-fed IL-37tg mice when compared with
WT mice (Fig. 4e–g). In line with these data, immunohis-
tochemistry demonstrated a reduced number of F4/80þ cells in
the adipose tissue of IL-37tg mice (Fig. 4i) and a reduced amount
of crown-like structures as compared with WT mice fed the HFD
(Fig. 4h). Next, we further explored whether recIL-37 limits
adipose tissue inﬂammation in Ob/Ob mice, an established obese
mouse model with enhanced adipose tissue inﬂammation.
Therefore, Ob/Ob mice were treated intraperitoneally with
recIL-37 for 2 weeks. IL-1b levels were robustly reduced ( 93%,
Po0.01 (t-test)), as was the secretion of pro-inﬂammatory IL-6
and CXCL1 in WAT of animals treated with recIL-37, as com-
pared with animals receiving vehicle only (Fig. 4j–l). Moreover,
similar changes were seen in mRNA expression of these
cytokines, although the treatment did not change the number
of macrophages that were present in the adipose tissue
(Supplementary Fig. 7).
To further understand the molecular pathways affected by
IL-37 during development of obesity, a microarray analysis of the
whole adipose tissue from HFD-fed WT and IL-37tg animals was
performed. Hierarchical clustering of the microarray results led to
a distinct separation of WT versus IL-37tg animals fed the HFD
for 16 weeks (Supplementary Fig. S8). Compared with the WT
mice, 1,125 genes were signiﬁcantly upregulated and 793 genes
were downregulated in the adipose tissue of the IL-37tg animals
(Po0.01).
Figure 5a shows the pathways that were regulated signiﬁcantly
different in the IL-37tg mice compared with WT mice, when
analysed using Cytoscape. In the adipose tissue of the IL-37tg
animals, several immune and inﬂammatory pathways including
Toll-like receptor (TLR) signalling were downregulated compared
with the WT mice. In line with downregulation of TLR signalling
pathways, qPCR analysis of TLR-2 and TLR-4, known to mediate
obesity-induced adipose tissue inﬂammation35–38, revealed
reduced expression levels of both TLRs in adipose tissue of
HFD-fed IL-37tg animals as compared with WT mice
(Supplementary Fig. S9b,c). Noticeably, expression levels of
TLR-1 increased similarly in both genotypes (Supplementary
Fig. S9a).
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In addition, the microarray data revealed upregulation of a
cluster of genes related to mitochondrial and oxidative phos-
phorylation in adipose tissue of HFD-fed IL-37tg animals as
compared with WT mice, suggesting that IL-37 may directly
inﬂuence speciﬁc metabolic pathways.
IL-37 affects AMPK activation in macrophages and adipocytes.
Although AMPK is a central regulator of cellular metabolism39,
its activation also results in several anti-inﬂammatory effects, for
example, by reduced production of pro-inﬂammatory cytokines
in response to LPS40. Activation of AMPK is known to have
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profound effects on adipose tissue, including anti-obesity
effects41. In related studies, transfection of THP-1 cells with
IL-37 resulted in 440% increase in phosphorylation of AMPK
associated with a 460% reduction in mammalian target of
rapamycin21. Therefore, we subsequently evaluated whether IL-37
affects AMPK signalling in adipocytes. Murine adipocytes were
treated with recombinant IL-37 precursor IL-37 for 1 h and
phosphorylation of AMPK was subsequently measured.
Adipocytes that were stimulated with recIL-37 displayed
increased phosphorylation of AMPK (Fig. 5b), revealing that
IL-37 activates AMPK signalling. In addition, the activity of ACC,
an important downstream target of AMPK, was also increased by
recIL-37 treatment (Fig. 5b). Furthermore, Sestrin 2, an important
activator of AMPK, was increased in the presence of IL-37 in the
HFD mice, suggesting a possible explanation by which AMPK
activity was increased (Supplementary Fig. 10). As activation of
AMPK is known to potently inhibit adipocyte differentiation42,
adipocytes from WT mice were subsequently differentiated in the
presence of recIL-37, and mRNA levels of lipogenic genes PPARg
and FAPB4 were measured. Indeed, recIL-37-treated cells
displayed reduced adipocyte differentiation as indicated by
reduced mRNA expression of FABP4 and PPARg (Fig. 5c,e).
In bone marrow-derived macrophages (BMDMs) from IL-37tg
animals, pAMPK levels were elevated compared with WT mice
(Fig. 5f) paralleled by reduced levels of CXCL1 secreted from
these cells after LPS (Fig. 5g). These data show that AMPK is a
key protein downstream of IL-37 signalling.
IL-37 in human adipose tissue relates to insulin sensitivity.
Although IL-37 is present in adipose tissue43, its role in
controlling inﬂammation in subjects with obesity and/or insulin
resistance remains unknown. Therefore, we determined IL-37
levels in subcutaneous adipose tissue samples obtained from a
cohort of 80 subjects with varying levels of body mass index
(BMI), insulin sensitivity and degree of adipose tissue
inﬂammation. We compared log-normalized levels of IL-37
gene expression values in human adipose tissue with adipose
tissue leptin levels, the homeostatic model for insulin resistance
(HOMA-IR) and markers of adipose tissue inﬂammation. IL-37
gene expression levels in adipose tissue were signiﬁcantly higher
in subjects with lower leptin protein levels (Fig. 6a). BMI was not
associated with IL-37 mRNA levels in adipose tissue (Fig. 6b). We
investigated whether the inﬂammatory status of the adipose
tissue, as quantiﬁed by the level of macrophage inﬁltration, was
associated with IL-37 expression. Indeed, the number of CD68-
positive cells in adipose tissue was inversely associated with
IL-37 mRNA expression levels (Fig. 6c). IL-37 expression was
associated with improved insulin sensitivity, as determined by the
HOMA-IR, such that individuals with a low HOMA-IR exhibited
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Figure 4 | IL-37 reduces inﬁltration of macrophages and lymphocytes into WAT. (a) Macrophages (F4/80þCD11bþ ), (b) NK cells (NK1.1þ ),
(c) cytotoxic T cells (CD3þCD8þCD4 ) and (d) regulatory T cells (CD3þCD4þCD8 ), measured with ﬂow cytometry. qPCR analysis of
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higher IL-37 mRNA levels in adipose tissue compared with
persons with a higher HOMA-IR (Fig. 6d). Lastly, and in line
with these ﬁndings, higher insulin levels were associated with
lower IL-37 mRNA levels, whereas plasma glucose levels were not
related to IL-37 adipose tissue expression levels (Supplementary
Fig. S11a,b).
Discussion
Adipose tissue inﬂammation is a key process in the development
of obesity-induced insulin resistance. We demonstrate here that
IL-1 family member IL-37 counteracts the detrimental effects of
HFD feeding on weight, adipose tissue inﬂammation and
systemic insulin resistance in IL-37tg mice. Moreover, treatment
with recIL-37 in vivo and in vitro represses adipose tissue
inﬂammation. We also report data suggestive of a similar
function in human subjects. Together, these ﬁndings identify
IL-37 as a potential new target to tackle obesity-induced insulin
resistance and type 2 diabetes.
First, these conclusions are based on the observations that
transgenic mice expressing human IL-37 show a reduction in
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weight gain, lower adipocyte mass and size, less adipose tissue
inﬂammation and less insulin resistance in response to HFD
feeding in comparison with WT mice fed the same diet. Second,
as IL-37tg mice show greater glucose tolerance after short-term
feeding, the effect of IL-37 is weight-independent. Third, IL-37
preserves IRS-1 tyrosine (Tyr) 941 phosphorylation, thereby
rescuing downstream insulin signalling. Fourth, IL-37 expression
in human adipose tissue is inversely correlated with adipose tissue
inﬂammation and the presence of insulin resistance. Thus, these
data support a link between IL-37 biology, adipose tissue
inﬂammation and insulin sensitivity.
As food intake was similar between IL-37tg and control
animals, other mechanisms probably underlie the decreased
weight gain in IL-37tg animals during HFD-induced obesity.
Interestingly, the microarray data revealed that oxidative
phosphorylation and respiratory activity in WAT of the IL-37tg
animals were increased compared with WT animals fed the HFD.
Moreover, we show that IL-37 directly activates AMPK signalling
and reduces adipocyte differentiation. This is in line with earlier
described ﬁndings that overexpression of IL-37 in THP-1 cells
increases AMPK and decreases mammalian target of rapamycin
levels21. Moreover, other anti-inﬂammatory agents induce AMPK
activation44. The increase of AMPK was accompanied by an
increased ACC activity, providing evidence that IL-37 can
activate metabolic pathways in adipocytes. It suggests the
involvement of AMPK activation in the protecting effects of
IL-37 against adipose tissue expansion on HFD feeding.
Interestingly, recent data revealed that IL-18 signalling
enhances FA oxidation via activation of AMPK signalling45. As
both IL-37 and IL-18 bind to the same IL-18 receptor a chain
(IL-18ra)24, our ﬁndings suggest that IL-37 can activate AMPK
signalling via similar mechanisms, leading to increased FA
oxidation and alleviation from development of obesity.
Consistent with this observation, an enhanced activity of BAT
may partly explain the protection against the development of
obesity in IL-37tg animals.
Importantly, IL-37 transgenic animals displayed markedly
reduced adipose tissue inﬂammation, illustrated by reduced
pro-inﬂammatory immune cell inﬁltration into the adipose tissue,
as demonstrated by FACS analysis, qPCR and immunohisto-
chemistry. Moreover, treatment of severely obese mice with
recIL-37 reduced adipose tissue cytokine secretion, independent
of body weight. In macrophages, the IL-37-dependent activation
of AMPK may be aimed at counterbalancing pro-inﬂammatory
actions. It has been previously shown that activation of AMPK in
macrophages by 5-amino-1-b-D-ribofuranosyl-imidazole-4-car-
boxamide (AICAR), speciﬁcally inhibits pro-inﬂammatory cyto-
kine production on LPS treatment40. Through its activation of
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AMPK, IL-37 may also directly inhibit inﬂammatory actions of
immune cells. An alternative mechanism for the reduced obesity-
induced inﬂammation is provided by our microarray analyses,
showing downregulation of TLR signalling in IL-37tg mice after
HFD. An inhibitory effect of IL-37 on TLR signalling in the
IL-37tg mice would be consistent with a reduced ability
to respond to FFA’s via triggering of TLR-2 or TLR-4
(refs 35–38,46) that can lead to macrophage activation47.
Previous ﬁndings have shown that IL-37 is a fundamental
inhibitor of the response to LPS21. Thus, during HFD-induced
inﬂammatory cell inﬁltration into the adipose tissue, a
comparable mechanism may be activated in the presence of
IL-37. Through its anti-inﬂammatory properties, IL-37 not only
reduces levels of pro-inﬂammatory cytokines but also prevents
excessive immune cell activation in adipose tissue21.
A probable molecular mechanism through which IL-37 exerts
its anti-inﬂammatory effects is binding to the IL-18ra24,48. There
are also data that demonstrate that exploitation of the properties
of single immunoglobulin IL-1R-related protein and IL-18ra are
both necessary for the protective effects of IL-37 (ref. 49). Single
immunoglobulin IL-1R-related protein engagement is known to
negatively regulate TLR and IL-1 signalling50, and may also
explain IL-37 inﬂammation-dampening effects in adipose tissue.
Indeed, the microarray data revealed that IL-37 acts as an
inhibitor of TLR and IL-1-mediated pathways, which conﬁrms
earlier ﬁndings21. Besides extracellular binding, IL-37 has been
shown to translocate to the nucleus where it may act as a
transcriptional modulator28, as is the case with nuclear
translocation of another member of the IL-1 family member
IL-1a51,52. Altogether, these mechanisms probably account for
the anti-inﬂammatory actions of IL-37 in the adipose tissue. The
reduction of body weight and subsequent local inﬂammation may
also account for the markedly enhanced adiponectin levels
measured in the transgenic animals, as higher adiponectin
levels are generally observed in lean individuals53. Conversely,
more inﬂammation is associated with lower adiponectin levels54.
In humans, we found that IL-37 expression in adipose tissue
was inversely related to HOMA-IR. In the animal model, the
presence of IL-37 protected against the detrimental effects on
glucose tolerance and insulin sensitivity after HFD feeding. The
effects of IL-37 appear independently of body weight changes, as
IL-37tg animals were also protected against glucose intolerance
on short-term HFD feeding that did not affect weight in either
group. Moreover, we showed that IL-37 can preserve insulin
sensitivity in vitro, by preserving phosphorylation of IRS-1 and
downstream Akt for insulin signalling, via inhibition of
inﬂammatory kinases JNK, ERK and IKKa/b that cause
inhibitory serine phosphorylation of the insulin receptor
substrate-1 (ref. 34). In addition, similar to IL-1 and IL-18
(refs 55–57), IL-37 affects the function of the insulin-producing
b-cells. It is known that obesity can lead to islet hypertrophy and
increased insulin secretion58–60. We showed that the presence of
IL-37 spared pancreatic islets from hypertrophy and excessive
insulin production, compared with WT mice. Overall, these
ﬁndings reveal a role for IL-37 in determining insulin sensitivity.
Inversely, reduced production of IL-37 may contribute to the
onset of insulin resistance as absence of IL-37 may promote
inﬂammation that directly interferes with insulin signalling
routes.
Currently, regulation of IL-37 expression or its mRNA stability
in human adipose tissue is unknown. Interestingly, IL-37 mRNA
expression is found in the adipocyte fractions of human adipose
tissue, suggesting that adipocytes are sensitive for stimuli that
induce IL-37 production. Repeated high levels of postprandial
free FAs probably serve as triggers for IL-1 expression61 and
may also regulate IL-37 expression in adipose tissue. The
co-expression of IL-37 next to IL-1 is therefore probably aimed
at counterbalancing inﬂammation during obesity. As humans
reveal an inverse correlation between inﬂammation in adipose
tissue and expression of IL-37, it is likely to be that subjects who
fail to express sufﬁcient IL-37 locally will develop higher levels of
inﬂammation.
All in all, our ﬁndings show that IL-37 is important during the
development of obesity by counteracting adipocyte differentia-
tion, HFD-induced adipose tissue inﬂammation and insulin
resistance. Moreover, increased IL-37 expression in human
adipose tissue is associated with enhanced insulin sensitivity
and a reduction in adipose tissue inﬂammation. IL-37 may
therefore be a target to mitigate the detrimental effects of obesity,
including type 2 diabetes mellitus.
Methods
Human subjects. Subcutaneous and visceral adipose tissues were obtained from
healthy donors. Characteristics of donors are listed in Table 1. For associations of
Table 1 | Subject characteristics of human adipose tissue
biopsies (values are mean±s.d.).
Paired VAT and
SAT samples (n¼ 17)
AT biopsies
(n¼80)
Age (years) 52±10 54±8
Body weight (kg) 84±12 82±15
BMI (kgm 2) 27±3 28±5
Adipose tissue depot VAT and SAT SAT
Fasting glucose (mmol l 1) 6.3±2.0 5.1±0.6
Sex: M (% of total) 11 (65%) 38 (48%)
BMI, body mass index; M, male; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue;
AT, adipose tissue.
Table 2 | Primers used for quantitative real-time PCR analysis.
Primer name Species Sequence forward (504 30) Sequence reverse (504 30)
36B4 Mouse AGCGCGTCCTGGCATTGTGTGG GGGCAGCAGTGGTGGCAGCAGC
MCP-1 Mouse CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG
F4/80 Mouse CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG
CD11c Mouse CTGGATAGCCTTTCTTCTGCTG GCACACTGTGTCCGAACTCA
TLR-1 Mouse TCAAGCATTTGGACCTCTCCT TTGTACCCGAGAACCGCTCA
TLR-2 Mouse AACCTCAGACAAAGCGTCAAATC ACCAAGATCCAGAAGAGCCAAA
TLR-4 Mouse TTCCTTCTTCAACCAAGAACATAGATC TTGTTTCAATTTCACACCTGGATAA
IL-37 Human CAGCCTCTGCGGAGAAAGGAAGT GTTTCTCCTTCTTCAGCTGAAGGGATGGAT
B2M Human ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
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IL-37 expression, subjects from the same CONTROL cohort were used. The total
number of individuals in the control cohort was 80. Some measurements were not
carried out in all subjects. Leptin was measured in n¼ 66 subjects, BMI in n¼ 47
subjects, CD68þ cells per 1,000 adipocytes in n¼ 52 subjects and HOMA-IR in
n¼ 61 subjects. All subjects gave informed consent. The studies were approved by
the ethical committee of the Radboud University Medical Centre, Nijmegen.
Mice. IL-37tg mice on a C57Bl/6 background have been reported21. WT C57/Bl6
animals were purchased from Jackson Laboratories. All animal procedures were
conducted under protocols approved by the animal experimentation committee of
Radboud University Medical Centre, Nijmegen. Body weight of the animals was
recorded weekly. Twenty male mice per genotype (10 weeks of age at the start of
the dietary intervention) were used in the 16-week diet-intervention experiment.
After a 2-week run-in period on LFD, mice were given LFD or HFD diet for 16
weeks, containing 10 or 45% kcal derived from fat, respectively (D12450B or 12451,
Research Diets, Inc.). To investigate whether IL-37 had a body weight-independent
effect, we performed a 1-week short-term high-fat study using a diet containing
60% kcal derived from fat (D12492, Research Diets). For this, ten male mice per
genotype were used (12 weeks of age at the start of the intervention).
Studies on glucose homeostasis. At the end of diet-intervention study, oGTT
and ITT tests were performed. Before the oGTT test, all 40 male animals were
fasted overnight and 2 g kg 1 glucose (D-glucose, Gibco, Invitrogen) was orally
administered. Before the ITT test, mice were fasted 6 h and insulin (0.75U kg 1)
was injected intraperitoneally. Blood glucose levels were determined with an
Accu-chek glucosemeter (Roche Diagnostics, Almere, The Netherlands) at stated
time points.
Cytokine measurements. Plasma concentrations of insulin (Crystal Chem Inc.,
IL, USA), adiponectin, leptin (both R&D Systems, Minneapolis, MN, USA) were
measured by ELISA. Leptin levels in human adipose tissue were measured with
Milliplex (Millipore, Billerica, MA, USA). IL-37 protein levels were measured to
determine levels in adipose tissue (R&D Systems).
Histology/immunohistochemistry. Morphometry of individual fat cells was
assessed using digital image analysis. Microscopic images were digitized in 24-bit
RGB (specimen level pixel size 1.28 1.28 mm2). Recognition of fat cells was
initially performed by applying a region-growing algorithm on manually indicated
seed points, and minimum Feret diameter was calculated. For detection of mac-
rophages/monocytes, an F4/80 antibody (Serotec, Puchheim, Germany) was used.
Visualization of the complex was done using 3,30-diaminobenzidine for 5min.
Negative controls were used by omitting the primary antibody. Haematoxylin and
eosin staining of sections was done using standard protocols. Crown-like structures
were counted with a microscope at a magniﬁcation of  20, at least four images per
sample. Human macrophages were visualized using CD68.
The parafﬁn-embedded pancreas sections (5 mm) were deparafﬁnized/
rehydrated in Clearene (Surgipath, IL, USA) followed by ethanol and PBS serial
rehydration. Antigen retrieval was completed in citrate buffer, pH 6.0, for 15min
using a steamer, and sections were blocked with CAS-BLOCK solution (Invitrogen,
NY, USA) for 1 h. Sections were then stained with guinea pig anti-insulin antibody
(1:600, Dako Cytomation, Glostrup, Denmark) and incubated overnight at 4 C.
Cy3-conjugated donkey-anti-guinea pig IgG (1:200, Jackson Immunoresearch,
West Grove, PA, USA) was used as a secondary antibody and incubated for 2 h at
25 C. Counterstaining was performed with 5 mgml 1 40 ,6-diamidino-2-
phenylindole (Sigma, Rehovot, Israel). Next, slides were mounted with PermaFluor
aqueous mounting medium (Thermo Scientiﬁc, MA, USA). Images were captured
using an Olympus BX60 microscope. At least 30 islets were selected at random and
analysed using the CellProﬁler software, version 2.0. Mean ﬂuorescent intensity
was calculated by dividing the total staining intensity of each islet by its area.
For quantiﬁcation of the islet area, b-cells were visualized by an
immunohistochemical approach using an antibody against insulin (sc9168, Santa
Cruz Biotechnology, Heidelberg, Germany). Quantiﬁcation was performed using
ImageJ software (version V1.47t). A total of n¼ 10 animals per group per genotype
were analysed.
Lipids. Cholesterol, triglycerides and glucose (Liquicolor, Human GmbH,
Wiesbaden, Germany) and free FAs (NEFA-C, WAKO Chemicals, GmbH, Neuss,
Germany) were measured enzymatically following the manufacturers’ protocols.
FACS analyses. After washing with DMEMþ 0.1% BSA and FACS buffer
(PBSþ 1% BSA), the stromal vascular fraction was extracted from the epididymal
mouse WAT or human adipose tissue by digestion with 0.02% collagenase type 1
(Gibco, Invitrogen on HBSS containing 2% FA-free BSA) for 1 h. Cells were ﬁltered
with a 100-mM ﬁlter and centrifuged at 200g for 10min. Floating MAs were
discarded and SVF was resuspended in erythrocyte lysis buffer (BD Pharmingen)
for 10min. Cells were washed twice with FACS buffer. Cells were divided into
two equal parts and incubated with ﬂuorescently labelled antibodies, including
CD45-ECD (Coulter), CD3-APC (BD Pharmingen), CD4-FITC (BD Pharmingen),
CD8-PE (BD Biosciences), CD11b-PE (Biolegend), F4/80-FITC (eBioscience),
NK1.1 (Biolegend) and CD19-PC7 (BD Pharmingen). Cells were measured with
an FC 500 Coulter Beckman. Gating strategy is shown in Supplementary Fig. 6.
RNA isolation and gene expression. Total RNA was isolated from adipose tissue
using TRIzol (Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. RNA was reverse-transcribed (iScript cDNA Synthesis Kit, Bio-Rad
Laboratories). Reverse transcription–PCR was performed using speciﬁc primers
(see Supplementary Table 1), power SYBR green master mix (Applied Biosystems,
Foster City, CA) using the Step-one Real-Time PCR system (Applied Biosystems).
For mice samples, we used 36B4 as a housekeeping gene to correct the values.
F4/80, MCP-1, and CD68 and human IL-37 were analysed. For human samples,
we used B2M as a housekeeping gene. Primers sequences are shown in Table 2.
Western blot analysis. For mouse and human samples, lysates were prepared
using a lysis buffer (50mM Tris (pH7.4), 150mM NaCl, 2mM EDTA,1% Nonidet
P-40, 50mM NaF and 0.25% sodium deoxycholate with PhosStop Phosphatase-
Inhibitor Cocktail tablet (Roche) and complete, EDTA-free protease-inhibitor
cocktail tablet (Roche). The homogenate was centrifuged at 4 C for 10min at
18,000 r.c.f. and the supernatant was used for western blot analysis. Equal amounts
of protein, as determined by a BCA protein assay (Thermo FisherScientiﬁc,
Rockford, IL) were separated using a polyacrylamide SDS–PAGE gel. After
SDS–PAGE, proteins were transferred to a nitrocellulose membrane using a
Trans-Blot Turbo Transfer System (Biorad) following the manufacturer’s instruc-
tions. The membrane was blocked with 5% (wt/vol) milk powder in Tris-buffered
saline (TBS)/Tween 20 for 1 h at room temperature followed by incubation over-
night at 4 C with an IL-37 antibody (R&D systems), AMPK or phospho-AMPK
antibodies (Cell Signaling) in 5% (wt/vol) milk powder/TBS/Tween 20 or with an
actin antibody (Sigma-Aldrich, St Louis, MO) in 5% milk powder in TBS/Tween
20. After overnight incubation, the blots were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies at a dilution of 1:5,000 in
5% (wt/vol) milk powder in TBS/Tween 20 for 1 h at room temperature and
subsequently developed with ECL plus (Thermo Scientiﬁc) according to the
manufacturer’s instructions. Bands were visualized using a ChemiDoc System
(Biorad) and quantiﬁed using Image lab software (Biorad).
From human HepG2 hepatoma cells, proteins were separated under reducing
conditions on 8% bis-acrylamide gels. Proteins were then blotted on polyvinylidene
diﬂuoride membranes. Blocking, incubation steps with ﬁrst/second antibodies, and
washing was performed using a SNAP i.d. protein detection system according to
the manufacturer’s instructions (Millipore). The following antibodies have been
used: anti-phospho-IRS1 (Tyr941), anti-IRS1, anti phospho-Akt (Ser473), anti
pan-Akt, anti-GAPDH (all Cell Signaling), anti-rabbit immunoglobulins/HRP and
anti-mouse immunoglobulins/HRP (both Dako). Bands were visualized using a
chemoluminescent substrate and chemoluminescent ﬁlms (GE Healthcare).
Uncropped images of immunoblottings are shown in Supplementary Fig. 12.
Cell culture. Human HepG2 hepatoma cells were seeded in 10-cm culture tissue
plates. Cells were transfected with either IL-37-speciﬁc or scrambled siRNAs using
siPORT NeoFX transfection reagent (Ambion). Cells were starved overnight in
DMEM/0.25% fat-free BSA. The next morning, cultures were stimulated with
25 ngml 1 TNF-a for 10min or 5 mgml 1 tunicamycin for 4 h, respectively.
Thereafter, HepG2s were stimulated with 10 nM insulin for 5min. The media were
decanted, plates were immediately placed on ice and washed with ice-cold PBS
containing phosphatase inhibitors. Protein extraction was performed with M-PER
protein extraction reagents containing protease and phosphatase inhibitors
according to the manufacturer’s instructions (Pierce).
Human SGBS cells were differentiated with or without recIL-37 (10 ngml 1).
Differentiation was done as previously described62. In short, the differentiation was
initiated by incubating the cells in medium (DMEM/F12, Gibco Life Technologies,
Bleiswijk, The Netherlands) without serum in the presence of 2 mmol l 1
rosiglitazone, 25 nmol l 1 dexamethasone, 0.5mmol l 1 methylisobutylxanthine,
0.1 mmol l 1 cortisol, 0.01mgml 1transferrin, 0.2 nmol l 1 triiodothyronine (all
from Sigma-Aaldrich, Zwijndrecht, The Netherlands) and 20 nmol l 1 insulin.
Four days later, the medium was only enriched by 0.1 mmol l 1 cortisol,
0.01mgml 1transferrin, 0.2 nmol l 1 triiodothyronine and 20 nmol l 1 insulin.
After 2 weeks, light microscopy pictures were taken at magniﬁcation of  20
and mRNA was isolated as described.
Microarray analysis. RNA isolated from adipose tissue from HFD-fed animals
was used for microarray analysis (n¼ 4 animals per group). RNA quality was
determined by analysis on the Agilent 2100 Bio-analyser, and all samples had an
RNA Integrity Number (RIN) score 48. The Ambion WT Expression kit (Life
Technologies) in conjunction with the Affymetrix GeneChip WT Terminal
Labelling kit (Affymetrix, Santa Clara, CA) was used to prepare labelled com-
plementary DNA from 100 ng of total RNA. Samples were hybridized on Affy-
metrix GeneChip Mouse Gene 1.0 ST arrays. Differences in gene expression
between WT and IL-37tg-derived epididymal tissue were determined using gene set
enrichment analysis. The Enrichment Map plug-in for Cytoscape was used for
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visualization and interpretation of the gene set enrichment analysis results. The
cut-off values were Po0.01.
Statistical analysis. Data are shown as the mean±s.e.m. Differences between
groups were statistically analysed using Student’s t test, and differences among
the four groups were analysed with analysis of variance followed by post-hoc
Bonferroni tests in Graphpad Prism 5.0. When necessary, results were
log-transformed to normalize the data. A P-valueo0.05 was considered signiﬁcant.
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